Mexdagry (Metformin Hydrochloride, Dapagliflozin)

Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while dapagliflozin blocks the SGLT2 transporter in the kidneys, limiting glucose reabsorption and increasing its excretion in urine. The dual action lowers plasma glucose through both decreased production and increased elimination.

The specific dose of Mexdagry is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of Mexdagry in pregnancy and lactation has not been definitively established. It should only be used if the potential benefits justify the possible risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Mexdagry, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mexdagry offers a combined mechanism—metformin’s insulin‑sensitising effect plus dapagliflozin’s renal glucose excretion—providing greater HbA1c reduction than metformin alone. Compared with separate tablets, the fixed‑dose simplifies regimens, while its efficacy is comparable to other SGLT2‑inhibitor‑based combinations.

Mexdagry tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain stability throughout the shelf life.

Mexdagry is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed.

The most serious adverse events include lactic acidosis (linked to metformin) and euglycemic diabetic ketoacidosis (linked to dapagliflozin). Both conditions are medical emergencies requiring immediate attention. Acute kidney injury and severe dehydration are also important risks, especially in patients with compromised renal function.

Mexdagry is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or dapagliflozin, acute or chronic metabolic acidosis, and in individuals with a history of lactic acidosis. It should also be avoided in patients with uncontrolled urinary tract infections.